Tin tức & Cập nhật
Lọc theo Chuyên ngành:
3-day remdesivir prevents hospitalization, death in COVID-19
A 3-day course of remdesivir may help stave off COVID-19–related hospitalization and death, according to results of the phase III PINETREE study.
3-day remdesivir prevents hospitalization, death in COVID-19
18 Oct 2021
Antiplatelet plus anticoagulant therapy linked to better outcomes in COVID-19
Hospitalized patients with COVID-19 who receive antiplatelet and anticoagulant drugs concurrently may fare better than those given only therapeutic anticoagulation, according to a study.
Antiplatelet plus anticoagulant therapy linked to better outcomes in COVID-19
18 Oct 2021
Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients
In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.
Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients
14 Oct 2021
Tocilizumab cuts COVID-19 mortality when administered during the early inflammatory stage
Tocilizumab does not seem to prevent the progression of the coronavirus disease 2019 (COVID-19) to critical disease but may still be valuable in severely ill patients when used during the early inflammatory stages, a recent study has found.
Tocilizumab cuts COVID-19 mortality when administered during the early inflammatory stage
13 Oct 2021
Older age, CRP portend deaths in COVID-19 patients with diabetes
Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.
Older age, CRP portend deaths in COVID-19 patients with diabetes
13 Oct 2021
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
While patients with haematological malignancies (HM) are able to mount a persistent antibody response against the spike (S) protein of the SARS-CoV-2 virus, early treatment with rituximab completely abolishes such response, a recent study has found. These findings could help inform coronavirus disease 2019 (COVID-19) vaccination policies for patients with HMs.
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
12 Oct 2021
Novel RT-PCR may help detect SARS-CoV-2 mutations tied to VoC
The Spike single-nucleotide polymorphism (SNP) assay, a single-reaction multiplex real-time RT-PCR, provides fast, inexpensive, and sensitive detection of specific mutations associated with SARS-CoV-2 variants of concern (VoC), according to data presented at ID Week 2021.
Novel RT-PCR may help detect SARS-CoV-2 mutations tied to VoC
12 Oct 2021
Tamibaroterone inhalable dry powder shows broad-spectrum activity against SARS-CoV-2, MERS and H1N1
Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 influenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.